Goldman Sachs Group began coverage on shares of Elanco Animal Health (NYSE:ELAN) in a report issued on Monday morning, The Fly reports. The brokerage issued a positive rating on the stock. The analysts noted that the move was a valuation call.

A number of other equities analysts have also commented on the company. UBS Group raised Elanco Animal Health from a sell rating to a neutral rating and cut their price target for the stock from $31.00 to $30.00 in a report on Thursday, August 15th. Zacks Investment Research lowered Elanco Animal Health from a hold rating to a sell rating in a report on Friday, September 6th. Guggenheim initiated coverage on Elanco Animal Health in a report on Wednesday, May 22nd. They issued a neutral rating for the company. Finally, Bank of America lowered Elanco Animal Health from a buy rating to a neutral rating and set a $30.00 price target for the company. in a report on Monday, August 26th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $33.64.

Elanco Animal Health stock opened at $28.74 on Monday. Elanco Animal Health has a one year low of $25.51 and a one year high of $37.61. The business has a fifty day moving average price of $29.34 and a 200-day moving average price of $31.56. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.07 and a quick ratio of 1.71. The firm has a market capitalization of $9.87 billion and a P/E ratio of 24.36.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $0.28 EPS for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.02. Elanco Animal Health had a return on equity of 7.83% and a net margin of 4.69%. The firm had revenue of $781.60 million during the quarter, compared to analyst estimates of $781.49 million. Elanco Animal Health’s revenue was up 1.5% compared to the same quarter last year. Sell-side analysts expect that Elanco Animal Health will post 1.08 earnings per share for the current fiscal year.

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 75,750 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was bought at an average price of $26.55 per share, with a total value of $2,011,162.50. Following the completion of the purchase, the chief executive officer now owns 470,006 shares of the company’s stock, valued at $12,478,659.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director R David Hoover acquired 15,000 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were acquired at an average cost of $26.96 per share, with a total value of $404,400.00. The disclosure for this purchase can be found here. Insiders have purchased 111,780 shares of company stock valued at $2,975,212 in the last three months. 0.04% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. Water Island Capital LLC purchased a new stake in Elanco Animal Health during the first quarter valued at about $27,000. Steward Partners Investment Advisory LLC purchased a new stake in Elanco Animal Health during the second quarter valued at about $32,000. Capital Investment Advisory Services LLC raised its position in Elanco Animal Health by 1,501.4% during the second quarter. Capital Investment Advisory Services LLC now owns 1,121 shares of the company’s stock valued at $36,000 after purchasing an additional 1,051 shares in the last quarter. Valeo Financial Advisors LLC raised its position in Elanco Animal Health by 376.7% during the second quarter. Valeo Financial Advisors LLC now owns 1,430 shares of the company’s stock valued at $48,000 after purchasing an additional 1,130 shares in the last quarter. Finally, Citizens Financial Group Inc RI purchased a new stake in Elanco Animal Health during the first quarter valued at about $48,000.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Recommended Story: Does the discount rate affect the economy?

The Fly

Analyst Recommendations for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.